185 Results for "

MMAE

" in MedChemExpress (MCE) Product Catalog:
Products (185)

185 Results for "MMAE" in MCE Product Catalog:

97
97 Publications Verification
Cat. No.: HY-15575
CAS No.: 646502-53-6
Purity:  99.94%
Synonyms: MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE; Vedotin
VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
loading...
    loading...
61
61 Cited Publications
Cat. No.: HY-15162
CAS No.: 474645-27-7
Purity:  99.97%
Synonyms: MMAE; SGD-1010
Research Areas:  

Cancer

Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-15162A
CAS No.: 2070009-72-0
Purity:  99.15%
Synonyms: Monomethyl auristatin E-d8; Deuterated labeled MMAE
MMAE-d8 is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-P9985
CAS No.: 2136633-23-1
Synonyms: RC48
Research Areas:  

Cancer

Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-100874
CAS No.: 3046395-46-1
Purity:  98.56%
Research Areas:  

Cancer

N3-PEG3-vc-PAB-MMAE is a synthesized agent-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor ) and 3-unit PEG linker. N3-PEG3-vc-PAB-MMAE shows potent antitumor activity. N3-PEG3-vc-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P99016
CAS No.: 1448664-46-7

Target:  

ADC Antibodies Nectin-4

Research Areas:  

Cancer

Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-111012
CAS No.: 2754384-60-4
Purity:  99.60%
Research Areas:  

Cancer

DBCO-(PEG)3-VC-PAB-MMAE is a agent-linker conjugate for ADC. DBCO-(PEG)3-VC-PAB-MMAE is made by Monomethyl auristatin E (HY-15162) conjugats to DBCO-(PEG)3-vc-PAB linker. DBCO-(PEG)3-VC-PAB-MMAE can be used for the research of cancer . DBCO-(PEG)3-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-100566
Purity:  99.24%
Research Areas:  

Cancer

SuO-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-164992
Synonyms: MRG002; Trastuzumab MMAE
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-100374
CAS No.: 644981-35-1
Purity:  99.76%
Research Areas:  

Cancer

Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-136314
CAS No.: 2129164-91-4
Purity:  99.18%
Research Areas:  

Cancer

DBCO-PEG4-VC-PAB-MMAE consists a ADC linker (DBCO-PEG4-VC-PAB) and a tubulin polymerization inhibitor MMAE (HY-15162). DBCO-PEG4-VC-PAB-MMAE can be used in the synthesis of antibody-agent conjugates (ADCs). MMAE is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. DBCO-PEG4-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-147239
CAS No.: 1818864-51-5
Purity:  99.93%
Research Areas:  

Cancer

MC-VA-PABC-MMAE is a agent-linker conjugate for ADC. MC-VA-PABC-MMAE contains the ADCs linker (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-126681
CAS No.: 2259318-46-0
Purity:  98.01%
Synonyms: NHS-VC-PAB-MMAE
Research Areas:  

Cancer

SC-VC-PAB-MMAE (NHS-VC-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P81056
Synonyms: MMAE; Monomethyl auristatin E; Monomethylauristatin E; Monomethylauristatin norephedrine; Toxin MMAE; MMAE toxin

Host:  

Rabbit

Application:  

ELISA

Reactivity:  

Species independent

loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-141604
CAS No.: 1182215-65-1
Purity:  99.90%
Synonyms: CDX-011; CR011-vcMMAE
Glembatumumab vedotin (CDX-011) is an ADC comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99151
CAS No.: 2088770-90-3
Synonyms: CAC-10

Research Areas:  

Cancer

Brentuximab (CAC-10) is a chimeric antibody targeting CD30. Brentuximab is conjugated with Monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107A). Brentuximab can be used for the research of cancer, such as lymphoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-131056
CAS No.: 2684216-48-4
Purity:  99.63%
Research Areas:  

Cancer

Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-164146
CAS No.: 2126083-82-5
BCN-HS-PEG2(vcPABC-MMAE)2 is a drug-linker conjugate for ADC consists an ADC linker and a tubulin polymerization inhibitor MMAE (HY-15162). BCN-HS-PEG2(vcPABC-MMAE)2 can be used in the synthesis of antibody-agent conjugates (ADCs) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W190943
CAS No.: 1869126-64-6
Research Areas:  

Cancer

Azido-PEG4-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH . Azido-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-141154
CAS No.: 1492056-71-9
Purity:  99.93%
Research Areas:  

Cancer

Amino-PEG4-Val-Cit-PAB-MMAE is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
loading...
    loading...